A safe, effective and efficient treatment for Laryngopharyngeal Reflux

LPR reportedly affects approximately 20% of the U.S. population. Symptoms include chronic cough, throatclearing, post-nasal drip, hoarseness, globus sensation, and dysphagia.

N-Zyme and Laryngopharyngeal Reflux

About N-Zyme

A proteolytic enzyme is the key therapeutic target in biomedical research of LPR

» Our Mission

Living with LPR

LPR symptoms reduce ones quality of life and contribute to life-threatening illnesses.

» What is LPR?

Our Research

How N-Zyme is addressing significant unmet clinical needs in LPR treatment.

» Learn more

Investor Relations

Our team is here to assist with all your questions. Get to know us better.

» Contact us» Our Team
reshaping the biomedical industry

We aim to create the world's first pepsin inhibitor as a revolutionary form of treatment for LPR.

Request Corporate Presentation

Get Informed

Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.

Thank you for joining us.
Something went wrong. Please contact us on info@nzymebiomedical.com
© 2021 N-Zyme Biomedical Inc.
All Rights Reserved